Ozone, Efferocytosis, and Neuropathic Pain

Study Background and Research Question

Neuropathic pain develops after nerve injury or disease and is characterized by spontaneous pain, sensory abnormalities, allodynia, and hyperalgesia. The condition affects an estimated 7%–10% of the population, according to the reference study, while available pharmacological treatments are limited by incomplete efficacy, adverse effects, tolerance, or dependence risk. This therapeutic gap has encouraged investigation of the immune and cellular events that sustain pain after peripheral nerve damage.

One underexplored process is the accumulation of apoptotic cells. When dying cells are not efficiently removed, intracellular material and damage-associated molecular patterns can maintain local inflammation. In nerve-injury settings, inflammatory cells and resident immune populations may then release cytokines and other mediators that increase neuronal excitability. Ruan and colleagues asked whether improving macrophage-mediated efferocytosis—the recognition and engulfment of apoptotic cells—could reduce this inflammatory environment and relieve neuropathic pain.

The central research question was therefore not simply whether ozone has an analgesic effect. The study tested whether ozone promotes apoptotic-cell clearance through a defined signaling pathway involving AMP-activated protein kinase (AMPK), growth arrest-specific 6 (Gas6), the Mer tyrosine kinase receptor (MerTK), and suppressor of cytokine signaling 3 (SOCS3).

Key Innovation from the Reference Study

The principal innovation is the positioning of efferocytosis as an upstream therapeutic mechanism in neuropathic pain. Rather than focusing only on neuronal transmission or generalized cytokine suppression, the study connects pain relief to the restoration of a macrophage housekeeping function: removal of apoptotic cells before they can perpetuate inflammatory signaling.

Its mechanistic model is that ozone activates AMPK in macrophages, increases Gas6 expression, and enhances Gas6-dependent activation of MerTK. MerTK is a recognized receptor involved in apoptotic-cell recognition and engulfment. The resulting increase in efferocytosis is associated with greater SOCS3 expression and lower levels of the inflammatory cytokines IL-1β, IL-6, and TNF-α. Notably, the investigators report an increase in Gas6 rather than Protein S, suggesting that these two related ligand systems are not interchangeable in this experimental context.

This is meaningful because it links three previously separable observations: apoptotic-cell accumulation after nerve injury, macrophage dysfunction, and neuroinflammation. The use of pathway inhibitors also moves the work beyond a descriptive association. The AMPK inhibitor compound C and the MerTK inhibitor UNC2541 eliminated the pain-relieving effect of ozone in the reported model, supporting the importance of this signaling axis.

Methods and Experimental Design Insights

The investigators used mice subjected to chronic constriction injury (CCI), a peripheral nerve-injury model that produces mechanical hypersensitivity. Ozone was administered at 15, 30, and 45 mg to examine dose-related effects on pain behavior, apoptotic-cell accumulation, and inflammatory responses. Mechanical sensitivity was then assessed alongside molecular and cellular analyses, allowing behavioral findings to be interpreted in relation to immune function rather than as an isolated analgesic endpoint. These design features are described in the open-access reference paper.

The complementary in vitro arm used bone-marrow-derived macrophages (BMDMs) exposed to apoptotic neutrophils. This reductionist system directly tested whether ozone changes macrophage phagocytic activity toward a defined apoptotic target. It also allowed the authors to investigate pathway components in macrophages without the full complexity of the injured nerve environment.

Mechanistic experiments evaluated AMPK activation, Gas6 and Protein S expression, MerTK activation, SOCS3 expression, and inflammatory cytokines. Pharmacological perturbation was particularly important: blocking AMPK with compound C tested whether AMPK activity was necessary for the response, while UNC2541 tested the contribution of MerTK. Because both interventions reversed the protective phenotype, the study offers pharmacological evidence for pathway dependence, although inhibitor specificity remains an important consideration when interpreting causality.

Protocol Parameters

• In vivo pain model: Use CCI mice when modeling peripheral nerve-injury-associated neuropathic pain and relate behavioral hypersensitivity to immune and apoptotic-cell outcomes, as in the reference study.
• Ozone comparison: The study evaluated 15, 30, and 45 mg ozone conditions; these are literature-backed study parameters rather than universally applicable dosing recommendations.
• Behavioral endpoint: Mechanical hypersensitivity was the reported pain-related outcome. A reproduction should preserve the behavioral assay and add prespecified molecular or cellular endpoints to distinguish analgesia from broader toxicity or motor effects.
• Macrophage efferocytosis assay: BMDMs were challenged with apoptotic neutrophils to test phagocytic clearance in vitro. Fluorescent labeling or another validated uptake method should be selected according to the laboratory’s imaging and flow-cytometry platform.
• Pathway perturbation: Compound C and UNC2541 were used in the study to interrogate AMPK and MerTK, respectively. Independent confirmation with genetic or orthogonal pharmacological approaches would strengthen pathway attribution.
• Inflammation panel: IL-1β, IL-6, and TNF-α were the principal inflammatory factors highlighted by the authors. Including untreated, injury-only, ozone-only, and inhibitor controls is a practical workflow recommendation for separating treatment effects from model effects.

Core Findings and Why They Matter

Among the tested conditions, 30 mg ozone significantly reduced mechanical hypersensitivity in CCI mice, according to the published results. The finding is important not because it establishes a clinical dose, which it does not, but because it identifies a dose condition associated with both behavioral improvement and enhanced immune-cell clearance.

Ozone also increased the phagocytic activity of BMDMs toward apoptotic neutrophils. This result supports the idea that macrophages are not merely passive responders to nerve injury. Their ability to remove dying cells can be modified, and that modification may influence the persistence of inflammation.

At the molecular level, ozone activated AMPK, increased Gas6, promoted MerTK signaling, and increased SOCS3 expression. The study did not report a corresponding increase in Protein S, which narrows the proposed mechanism toward a Gas6-MerTK route. In parallel, IL-1β, IL-6, and TNF-α were suppressed. Together, these results support a sequence in which enhanced efferocytosis is coupled to a more inflammation-resolving macrophage state.

The inhibitor experiments provide the strongest functional evidence. Both AMPK inhibition with compound C and MerTK inhibition with UNC2541 abolished ozone-mediated relief of CCI-induced pain. This pharmacological reversal is consistent with the proposed AMPK/Gas6-MerTK/SOCS3 pathway and suggests that efferocytosis is not simply correlated with behavioral improvement. Nevertheless, the result should be interpreted as pathway support rather than definitive proof of a linear molecular cascade, because inhibitor off-target effects and pathway feedback cannot be excluded.

Conceptually, the work broadens the therapeutic discussion around neuropathic pain. It suggests that restoring the handling of apoptotic cells may reduce the inflammatory stimuli that maintain pain. This may be particularly relevant in disease states where cell death, macrophage recruitment, and cytokine release occur together.

Comparison with Existing Internal Articles (if available)

The internal article Ozone Enhances Macrophage Efferocytosis to Relieve Neuropathic Pain presents the same study in a shorter, mechanism-oriented format. Its emphasis on apoptotic-cell clearance and the AMPK/Gas6-MerTK/SOCS3 pathway is consistent with the primary paper. The reference study, however, is more useful for literature-focused interpretation because it shows how the in vivo CCI model, BMDM experiments, inflammatory readouts, and inhibitor studies fit together. The internal article is therefore best used as a concise orientation resource, while the original publication should anchor experimental claims and citation.

Limitations and Transferability

Several limitations constrain how broadly these findings should be applied. First, CCI is one experimental model of neuropathic pain. It reproduces important features of peripheral nerve injury but cannot represent the full biological diversity of chemotherapy-induced neuropathy, diabetic neuropathy, spinal cord injury, or central pain syndromes. Replication in additional models would clarify whether the efferocytosis mechanism is general or injury-specific.

Second, the reported ozone conditions should not be treated as a validated human dosing framework. Dose translation requires independent assessment of exposure, tissue distribution, safety, treatment timing, and delivery route. The behavioral benefit observed in mice is a preclinical signal, not evidence of clinical efficacy.

Third, compound C and UNC2541 provide useful mechanistic perturbations but are not substitutes for genetic validation. Conditional AMPK or MerTK loss-of-function approaches, macrophage-specific manipulations, and rescue experiments would help determine whether the pathway operates within macrophages and whether Gas6 is required in the proposed sequence.

Fourth, the reference study connects efferocytosis with inflammatory suppression and pain behavior, but it does not establish that changes in extracellular pH drive the AMPK/Gas6-MerTK/SOCS3 response. Nor does it demonstrate that pH measurement can replace direct assays of efferocytosis, cytokines, or neuronal sensitivity. These distinctions matter when adapting the findings to analytical workflows outside the original study.

Overall, the work provides a credible preclinical framework for studying macrophage clearance in neuropathic pain, while leaving questions about cell specificity, long-term effects, model diversity, and clinical translation open.

Research Support Resources

Why this cross-domain matters, maturity, and limitations

Researchers studying the same inflammatory microenvironment may also wish to monitor acid–base conditions as a contextual variable. This is a complementary measurement strategy, not a mechanism demonstrated by the reference paper: the ozone study did not use a pH indicator, and its findings do not show that extracellular acidity causes altered efferocytosis. A pH readout can therefore support interpretation of ion transport, metabolism, or microenvironmental pH regulation alongside the paper’s macrophage and cytokine endpoints, but it should not be used to infer AMPK or MerTK activation by itself.

For such adjunct workflows, researchers can use BCECF (2',7'-bis(carboxyethyl)-5(6)-Carboxyfluorescein) (SKU C5694), a cell-impermeant dual-excitation ratiometric pH indicator. Its emission ratio at 535 nm after excitation at 490 versus 440 nm can support extracellular pH measurement when calibrated for the experimental system, making it relevant as a fluorescent pH probe for ion transport studies, a probe for cellular metabolism pH monitoring, a microenvironmental pH regulation assay, or an acid-base homeostasis research tool. Because it was not part of the ozone experiments, its use should remain an independent analytical complement rather than a replacement for efferocytosis, pathway, or pain measurements.